Investors

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Aldeyra Therapeutics Abstract Accepted at 2015 American Academy of Allergy Asthma & Immunology Annual Meeting
Novel Anti-Inflammatory Data Selected for Late-Breaking Poster Presentation
View HTML
Toggle Summary Aldeyra Therapeutics Abstract Accepted for Presentation at the 2015 Multinational Association of Supportive Care in Cancer - International Society of Oral Oncology (MASCC-ISOO) Annual Meeting
LEXINGTON, Mass., April 23, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that novel data on its lead product candidate, NS2, have been accepted
View HTML
Toggle Summary Aldeyra Therapeutics Abstracts Accepted for Presentation at the 2015 Annual Meeting of the Association for Research in Vision and Ophthalmology
LEXINGTON, Mass. , Feb. 2, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that novel data on its lead product candidate, NS2, has been accepted
View HTML
Toggle Summary Aldeyra Therapeutics Announces $2.0 Million Private Placement
LEXINGTON, Mass., Jan. 20, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that it has entered into a definitive purchase agreement with a leading
View HTML
Toggle Summary Aldeyra Therapeutics Announces $7.79 Million Private Placement
LEXINGTON, Mass. , Jan. 13, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that it has entered into a definitive purchase agreement to raise
View HTML
Toggle Summary Aldeyra Therapeutics Announces 2016 Research and Development Day
LEXINGTON, MA -- (Marketwired) -- 09/09/16 -- Aldeyra Therapeutics, Inc. ( NASDAQ : ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that it will host a Research and Development Day to discuss the company's
View HTML
Toggle Summary Aldeyra Therapeutics Announces 2017 Research and Development Day
LEXINGTON, Mass. , Sept. 27, 2017 /PRNewswire/ -- Aldeyra Therapeutics , Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity today announced that it will host
View HTML
Toggle Summary Aldeyra Therapeutics Announces 2018 Research Day
LEXINGTON, Mass. , June 20, 2018 /PRNewswire/ --  Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that it will host a Research Day to
View HTML
Toggle Summary Aldeyra Therapeutics Announces Agreement with Johnson & Johnson Innovation to Advance Novel Immune-Modulating Drugs for Systemic Inflammatory Diseases
LEXINGTON, Mass. , Feb. 27, 2018 /PRNewswire/ -- Aldeyra Therapeutics , Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with inflammatory diseases, today announced that it has entered into a collaborative
View HTML
Toggle Summary Aldeyra Therapeutics Announces Clinical Development Update for Phase 3 Programs
LEXINGTON, MA -- (Marketwired) -- 01/25/17 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) Noninfectious Anterior Uveitis: Enrollment of first-ever vehicle-controlled Phase 3 clinical trial is expected to begin in the second quarter of 2017. Sjögren-Larsson Syndrome: Enrollment of first-ever Phase 3
View HTML